597 related articles for article (PubMed ID: 18069765)
21. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
Nobili S; Checcacci D; Filippelli F; Del Buono S; Mazzocchi V; Mazzei T; Mini E
J Chemother; 2008 Oct; 20(5):622-31. PubMed ID: 19028627
[TBL] [Abstract][Full Text] [Related]
22. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
[TBL] [Abstract][Full Text] [Related]
23. A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer.
Chiesa MD; Buti S; Tomasello G; Negri F; Buononato M; Brunelli A; Lazzarelli S; Brighenti M; Donati G; Passalacqua R
Tumori; 2007; 93(3):244-7. PubMed ID: 17679458
[TBL] [Abstract][Full Text] [Related]
24. Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study.
Calvo E; Cortés J; Rodríguez J; Fernández-Hidalgo O; Rebollo J; Martín-Algarra S; García-Foncillas J; Martínez-Monge R; de Irala J; Brugarolas A
Clin Colorectal Cancer; 2002 Aug; 2(2):104-10. PubMed ID: 12453325
[TBL] [Abstract][Full Text] [Related]
25. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
[TBL] [Abstract][Full Text] [Related]
26. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
[TBL] [Abstract][Full Text] [Related]
27. Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies.
Comella P; Casaretti R; De Rosa V; Avallone A; Izzo F; Fiore F; Lapenta L; Comella G
Ann Oncol; 2002 Dec; 13(12):1874-81. PubMed ID: 12453855
[TBL] [Abstract][Full Text] [Related]
28. FDA drug approval summaries: oxaliplatin.
Ibrahim A; Hirschfeld S; Cohen MH; Griebel DJ; Williams GA; Pazdur R
Oncologist; 2004; 9(1):8-12. PubMed ID: 14755010
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.
Van Cutsem E; Rivera F; Berry S; Kretzschmar A; Michael M; DiBartolomeo M; Mazier MA; Canon JL; Georgoulias V; Peeters M; Bridgewater J; Cunningham D;
Ann Oncol; 2009 Nov; 20(11):1842-7. PubMed ID: 19406901
[TBL] [Abstract][Full Text] [Related]
30. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence.
Wade R; Duarte A; Simmonds M; Rodriguez-Lopez R; Duffy S; Woolacott N; Spackman E
Pharmacoeconomics; 2015 May; 33(5):457-66. PubMed ID: 25616671
[TBL] [Abstract][Full Text] [Related]
31. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.
Sobrero A; Ackland S; Clarke S; Perez-Carrión R; Chiara S; Gapski J; Mainwaring P; Langer B; Young S;
Oncology; 2009; 77(2):113-9. PubMed ID: 19628950
[TBL] [Abstract][Full Text] [Related]
32. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
[TBL] [Abstract][Full Text] [Related]
33. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
Masi G; Allegrini G; Cupini S; Marcucci L; Cerri E; Brunetti I; Fontana E; Ricci S; Andreuccetti M; Falcone A
Ann Oncol; 2004 Dec; 15(12):1766-72. PubMed ID: 15550581
[TBL] [Abstract][Full Text] [Related]
34. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study.
Seium Y; Stupp R; Ruhstaller T; Gervaz P; Mentha G; Philippe M; Allal A; Trembleau C; Bauer J; Morant R; Roth AD
Ann Oncol; 2005 May; 16(5):762-6. PubMed ID: 15817597
[TBL] [Abstract][Full Text] [Related]
35. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200.
Giantonio BJ; Levy DE; O'dwyer PJ; Meropol NJ; Catalano PJ; Benson AB;
Ann Oncol; 2006 Sep; 17(9):1399-403. PubMed ID: 16873427
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
37. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.
Raoul JL; Van Laethem JL; Peeters M; Brezault C; Husseini F; Cals L; Nippgen J; Loos AH; Rougier P
BMC Cancer; 2009 Apr; 9():112. PubMed ID: 19366444
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
Mochizuki S; Yoshino T; Kojima T; Fuse N; Ikematsu H; Minashi K; Yano T; Tahara M; Kaneko K; Doi T; Koike K; Ohtsu A
Jpn J Clin Oncol; 2010 Oct; 40(10):933-7. PubMed ID: 20494948
[TBL] [Abstract][Full Text] [Related]
39. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES).
Pinter T; Klippel Z; Cesas A; Croitoru A; Decaestecker J; Gibbs P; Hotko Y; Jassem J; Kurteva G; Novotny J; O'Reilly S; Salek T; Reiner M; Morrow PK; Choi MR; Whittaker S; Blanke C
Clin Colorectal Cancer; 2017 Jun; 16(2):103-114.e3. PubMed ID: 28038865
[TBL] [Abstract][Full Text] [Related]
40. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Loupakis F; Cremolini C; Masi G; Lonardi S; Zagonel V; Salvatore L; Cortesi E; Tomasello G; Ronzoni M; Spadi R; Zaniboni A; Tonini G; Buonadonna A; Amoroso D; Chiara S; Carlomagno C; Boni C; Allegrini G; Boni L; Falcone A
N Engl J Med; 2014 Oct; 371(17):1609-18. PubMed ID: 25337750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]